# Coya Therapeutics, Inc.: overview

COYA · Nasdaq · CIK 1835022 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/coya.md) · [Financials](/companies/coya/financials.md) · [Filings](/companies/coya/filings.md) · [Insiders](/companies/coya/insiders.md)

Latest reported revenue: [$243.7k](/filings/0001193125-26-343481.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-343481).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0000950170-24-121837.md) | [2.0 d](/filings/0001193125-26-107281.md) | [258](/filings/0001193125-26-218201.md) | [164](/filings/0001193125-26-343481.md) | [3,564](/filings/0001193125-25-276058.md) | [3,960 d](/filings/0001193125-26-107281.md) | [251](/filings/0001193125-26-218201.md) | [244](/filings/0001193125-26-343481.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [(209031.5%) d](/filings/0001193125-26-107281.md) | [(2976.9%)](/filings/0001193125-26-218201.md) | [(3920.5%)](/filings/0001193125-26-343481.md) | [(68.3%)](/filings/0001193125-25-276058.md) | [(152.3%) d](/filings/0001193125-26-107281.md) | [(3042.1%)](/filings/0001193125-26-218201.md) | [(2891.1%)](/filings/0001193125-26-343481.md) |
| Net margin | % | not reported | [(149373.8%) d](/filings/0001193125-26-107281.md) | [(2833.4%)](/filings/0001193125-26-343481.md) | [(3725.2%)](/filings/0001193125-26-343481.md) | [(59.4%)](/filings/0001193125-25-276058.md) | [(144.2%) d](/filings/0001193125-26-107281.md) | [(2869.6%)](/filings/0001193125-26-343481.md) | [(2723.4%)](/filings/0001193125-26-343481.md) |
| Diluted EPS | $ per share | [(0.26)](/filings/0001193125-25-276058.md) | not reported | [(0.44)](/filings/0001193125-26-218201.md) | [(0.36)](/filings/0001193125-26-343481.md) | [(0.13)](/filings/0001193125-25-276058.md) | not reported | [(0.32)](/filings/0001193125-26-218201.md) | [(0.28)](/filings/0001193125-26-343481.md) |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | [0.0](/filings/0000950170-24-033161.md) | [6,002](/filings/0000950170-25-040782.md) | [3,554](/filings/0001193125-26-107281.md) | [7,946](/filings/0001193125-26-107281.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(131.7%)](/filings/0000950170-25-040782.md) | [(485.4%)](/filings/0001193125-26-107281.md) | [(283.9%)](/filings/0001193125-26-107281.md) |
| Net margin | % | not reported | not reported | [(133.1%)](/filings/0000950170-25-040782.md) | [(418.7%)](/filings/0001193125-26-107281.md) | [(267.1%)](/filings/0001193125-26-107281.md) |
| Diluted EPS | $ per share | [(1.89)](/filings/0000950170-23-010599.md) | [(4.73)](/filings/0000950170-24-033161.md) | [(0.79)](/filings/0000950170-25-040782.md) | [(0.98)](/filings/0001193125-26-107281.md) | [(1.27)](/filings/0001193125-26-107281.md) |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/coya/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [DME Capital Management, LP](/funds/1489933.md) | 2026-06-30 | $13.7m | 2,335,540 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.9m | 842,220 |  | Reduced −2,693 |
| [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $4.7m | 800,000 |  | Unchanged |
| [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $3.7m | 631,912 |  | Reduced −343,492 |
| [CM Management, LLC](/funds/1841857.md) | 2026-06-30 | $2.3m | 400,000 |  | Added +25,000 |
| [PRIVATE MANAGEMENT GROUP INC](/funds/1142031.md) | 2026-06-30 | $2.2m | 384,217 |  | Added +15,121 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.5m | 249,793 |  | Added +24,001 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.3m | 228,243 |  | Reduced −5,159 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.1m | 192,986 |  | Added +89,022 |
| [Prosight Management, LP](/funds/1617201.md) | 2026-06-30 | $994.5k | 170,000 |  | Reduced −250,360 |

## Recent filings

[All 230 filings](/companies/coya/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-14 | 12:30 ET | [8-K](/filings/0001193125-26-421066.md) | 8.01 Other events | 0001193125-26-421066 |
| 2026-10-05 | 12:30 ET | [8-K](/filings/0001193125-26-413218.md) | 8.01 Other events | 0001193125-26-413218 |
| 2026-09-15 | 12:15 ET | [8-K](/filings/0001193125-26-391378.md) | 8.01 Other events | 0001193125-26-391378 |
| 2026-08-11 | 12:06 ET | [10-Q](/filings/0001193125-26-343481.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343481 |
| 2026-08-11 | 12:03 ET | [8-K](/filings/0001193125-26-343473.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343473 |
| 2026-08-07 | 21:00 ET | [8-K/A](/filings/0001193125-26-340449.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-340449 |
| 2026-06-25 | 21:00 ET | [8-K](/filings/0001193125-26-282989.md) | 5.07 Shareholder vote results | 0001193125-26-282989 |
| 2026-05-13 | 12:30 ET | [DEF 14A](/filings/0001193125-26-220688.md) | Proxy statement, period 2026-06-25 | 0001193125-26-220688 |
| 2026-05-12 | 12:48 ET | [8-K](/filings/0001193125-26-218282.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-218282 |
| 2026-05-12 | 11:41 ET | [10-Q](/filings/0001193125-26-218201.md) | Quarterly report, period 2026-03-31 | 0001193125-26-218201 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-107281.md), filed Mar 16, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1746c8f4-8654-4198-bbc8-6adaca0a6788)

## About the filer

- CIK: 1835022
- Tickers: COYA
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.